Dry Eye Disease- Pipeline Insight, 2022

Dry Eye Disease- Pipeline Insight, 2022

DelveInsight’s, “Dry Eye Disease- Pipeline Insight, 2022” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Dry Eye Disease: Understanding Dry Eye Disease: Overview Dry eye disease is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and subacute inflammation of the ocular surface. Dry eyes can occur when tear production and drainage are not in balance. People with dry eyes either do not produce enough tears or their tears are of a poor quality. Dry eyes can develop for many reasons, including: Age, gender, medications, medical conditions (people with rheumatoid arthritis, diabetes, and thyroid problems are more likely to have symptoms of dry eyes. Also, problems with inflammation of the eyelids (blepharitis), inflammation of the surfaces of the eye, or the inward or outward turning of eyelids can cause dry eyes to develop) and other factors such as long-term use of contact lenses can be a factor in the development of dry eyes. Refractive eye surgeries, such as LASIK, can decrease tear production and contribute to dry eyes. People with dry eyes may experience irritated, gritty, scratchy or burning eyes; a feeling of something in their eyes; excess watering; and blurred vision. Symptoms include: Redness, stinging, scratching, or burning sensations, light sensitivity, watery eyes, stringy mucus near the eye and a blurry Vision. Dry eyes can be diagnosed through a comprehensive eye examination. Treatments for dry eyes aim to restore or maintain the normal amount of tears in the eye to minimize dryness and related discomfort and to maintain eye health. The primary approaches used to manage and treat dry eyes include adding tears using over-the-counter artificial tear solutions, conserving tears, increasing tear production, and treating the inflammation of the eyelids or eye surface that contributes to the dry eyes. “Dry Eye Disease- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Eye Disease pipeline landscape is provided which includes the disease overview and Dry Eye Disease treatment guidelines. The assessment part of the report embraces, in depth Dry Eye Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Eye Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The therapies under development are focused on novel approaches to treat/improve Dry Eye Disease. Dry Eye Disease Emerging Drugs Chapters This segment of the Dry Eye Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Dry Eye Disease Emerging Drugs • Reproxalap: Aldeyra Therapeutics Reproxalap, is a novel small molecule drug candidate for Dry Eye. By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease. In a number of clinical trials, reproxalap demonstrated consistent statistically significant and clinically relevant activity. In a Phase II b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease. • Timbetasin: RegeneRx Biopharmaceuticals RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that Tβ4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea. • Visomitin: Mitotech Visomitin, contains a novel small molecule cardiolipin peroxidation inhibitor, specifically developed to target ophthalmic disorders such as dry eye syndrome, uveitis and age-related macular degeneration, in an eye drop formulation for ease of administration. Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector. Further product details are provided in the report…….. Dry Eye Disease: Therapeutic Assessment This segment of the report provides insights about the different Dry Eye Disease drugs segregated based on following parameters that define the scope of the report, such as: • Major Players in Dry Eye Disease There are approx. 50+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. phase III include, RegeneRx Biopharmaceuticals. • Phases DelveInsight’s report covers around 50+ products under different phases of clinical development like • Late stage products (Phase III) • Mid-stage products (Phase II) • Early-stage product (Phase I) along with the details of • Pre-clinical and Discovery stage candidates • Discontinued & Inactive candidates • Route of Administration Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as • Intra-articular • Intraocular • Intrathecal • Intravenous • Ophthalmic • Oral • Parenteral • Subcutaneous • Topical • Transdermal • Molecule Type Products have been categorized under various Molecule types such as • Oligonucleotide • Peptide • Small molecule • Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Dry Eye Disease: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dry Eye Disease therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Eye Disease drugs. Dry Eye Disease Report Insights • Dry Eye Disease Pipeline Analysis • Therapeutic Assessment • Unmet Needs • Impact of Drugs Dry Eye Disease Report Assessment • Pipeline Product Profiles • Therapeutic Assessment • Pipeline Assessment • Inactive drugs assessment • Unmet Needs Key Questions Current Treatment Scenario and Emerging Therapies: • How many companies are developing Dry Eye Disease drugs? • How many Dry Eye Disease drugs are developed by each company? • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Eye Disease? • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dry Eye Disease therapeutics? • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? • What are the clinical studies going on for Dry Eye Disease and their status? • What are the key designations that have been granted to the emerging drugs? Key Players • TearSolutions • HanAll Biopharma • Aldeyra Therapeutics • RegeneRx Biopharmaceuticals • Mitotech • Novaliq • Oyster Point Pharma • Aerie Pharmaceuticals • Azura Ophthalmics • Stuart Therapeutics • Surface Ophthalmics • Glaukos Corporation Key Products • Reproxalap • Timbetasin • Visomitin • NOV03 • HL036 • OC-01 • CyclASol • Lacripep • HBM9036 • AR15512 • AZR MD 001 • ST-100 • SURF-100 • SURF-200 • GLK-301

Please Note: It will take 7-10 business days to complete the report upon order confirmation.